A novel variant of the chimerical MLL-AF10 mRNA transcript method developed from an asymmetrical PCR method was detected in a pediatric patient with acute myeloid leukemia previously described by us. 
erical gene products and to find new recombination partners to the MLL gene, we have designed a new technique, which we designate asymmetrical RT-PCR (ART-PCR). The procedure is outlined in Figure 1 and is done on mRNA products.
Introduction
A two-step PCR is used to amplify fragments containing the site of translocation within the MLL gene. The first step in the A number of different chromosomal translocations are method is a PCR using a biotinylated specific MLL primer and observed in leukemic cells from patients with acute myeloid partly degenerate primers with fixed 3Ј ends, which will leukemia (AML).
1 In many, the translocations lead to prohybridize sporadically within a statistically defined range duction of chimerical proteins with an accidental role in the along the unknown sequence flanking the MLL gene. The five transcriptional regulation. Thus, the MLL gene (also called nucleotides at the 3Ј end of the primers are designed not to ALL-1, Htrx-1, HRX) 2-5 is involved in various translocations hybridize to the MLL sequence. The probability of hybridizing and forms chimerical products with more than 11 different to a random nucleotide pentamer sequence will be one out genes. 3, 4, [6] [7] [8] [9] [10] Moreover, variations in the breakpoint and splice of 1024. Using streptavidin-coated magnetic beads, the PCR variants are observed. The MLL protein has the characteristics product with the biotin tag is extracted from the first PCR. In of a transcription factor with a number of structural domains; a second PCR, a nested MLL primer and a primer derived from an AT-hook and three zinc fingers (LAP). In most cases only the conserved 5Ј end of the random primer sequences are the AT hook is preserved in the chimerical protein after the used with the purified products from the first PCR as template. translocation.
11
The PCR products are subjected to further analysis including The t(10;11)(p12;q23) is observed in both pediatric and determination of the DNA sequence. To exclude PCR fragadult leukemia patients. 10 In the t(10;11) translocations the ments composed of only MLL sequences, a diagnostic restric-MLL gene is fused to the AF10 gene. 10, 12 However, in several tion enzyme analysis is done using an enzyme that recognizes patient samples cytogenetic analyses have revealed a complex sequences in the breakpoint region. 13 For the MLL cDNA, the pattern of recombinations affecting genes other than MLL and enzyme BsmI is used, see Figure 2c . AF10. 11 The AF10 protein carries both zinc finger and leucine zipper domains. In the AF10 gene the junction points are distributed over the entire gene. The only functional domain pre-ART-PCR to detect a new fusion mRNA served in the chimerical proteins is the leucine zipper.
Interestingly, the breakpoints in pediatric cases have preThe patient information is given in the Materials and methods viously been described to be restricted to a narrow region in section. RNA was extracted and converted to cDNA before the AF10 coding region, whereas in adults the junctions are the ART-PCR analysis was performed. In the first round we distributed all over the entire AF10 coding region. 12 Contrary used four different random primers designated RP1-4. After to this, we now describe a new MLL-AF10 fusion mRNA in a the first round of PCR no bands were usually visible on the pediatric patient, in which the fusion point in the AF10 mRNA agarose gel (Figure 2a ). After the dynabead purification and is placed approximately 1000 bp further downstream than the second round of PCR, we detected in samples originating previously described for pediatric cases. For the characterizfrom first round PCR with the random primer RP2, a DNA ation of the new fusion mRNA, we used a novel ART-PCR fragment of 422 bp ( Figure 2b, Figure 3) . Absence of MLL cDNA was between the 16 940 primer site and the BsmI aration of mRNA from the leukemic cells as template. Indeed, we detected a PCR product with the expected size as the only site located roughly 200 bp in the 3Ј direction. In Figure 2c , it is shown that the PCR fragment from the second round of product, clearly visible on the agarose gel ( Figure 4 ). The following DNA sequence analysis of this PCR product revealed PCR did not carry a BsmI site indicating that the fragment did not originate from the native MLL mRNA.
a sequence similar to that previously described, indicating the presence of the identical fusion mRNA.
DNA sequence analysis
Materials and methods To demonstrate that the new fragment was a product of a chromosomal translocation, we extracted the PCR fragment Patient material from the agarose gel and determined the DNA sequence using the primers 16940 and Tag (Table 1 ). Analysis of the DNA A previously healthy 9-year-old boy presented in September 1990 with a fever, weight loss and sore throat. AML FAB-type sequence using the GCG sequence analysis package showed that the amplified PCR fragment was a product of a new MLL-M5 was diagnosed by trephine biopsy. The liver and spleen were enlarged below the costal margin 9 and 8 cm, respect-AF10 fusion mRNA. The point of recombination in the MLL gene was determined to be between exon 5 and 6 in the ively. At diagnosis the white blood cell count was 146 × 10 9 /l with 100% myeloblasts, hemoglobin was 6.3 mmol/l, and the cDNA and between the base pairs 1930 and 1931 of the AF10 cDNA sequence. 12 The recombination results in an in-frame platelet count was 79 × 10 9 /l. The bone marrow was maximally hyperplastic, completely dominated by cloracetatefusion of MLL and AF10 coding sequences probably being able to produce a new chimerical protein. Relative to the preesterase negative myoblast. Immunophenotyping revealed the patient to be CD13 + , CD14 − , CD33 + , and HLA class II + . viously described points of fusion between the MLL and AF10 genes the position 1930/1931 in AF10 is therefore new. The Cytogenetic analysis by Giemsa banding of 10 bone marrow metaphases showed a karyotype with translocation size of the chimerical protein is predicted to be 1545 amino acids. t(10;11)(q23;q25) [10] . The boy was treated according to the Nordic Pediatric Hematology and Oncology group NOPHO-88 AML protocol.
14 One month after one course of thioguanine, cytosine Specific PCR analysis arabinoside and etoposide, his bone marrow was in remission. He then received three further courses of chemotherapy To show that the chimerical product determined by the ART-PCR procedure was present in the leukemic cells, we conbefore bone marrow harvest and a subsequent autologous bone marrow transplantation in October 1990. He remained structed PCR primers binding to the MLL and AF10 sequences and performed a classical RT-PCR using an independent prepin remission until a bone marrow relapse was diagnosed in May 1991. At this point, cytogenetic analysis in addition to that previously seen t(10;11) also revealed t(1;19)(q21;q13/p13). In contrast, his immunophenotype was unaltered. He died 1 month after the relapse.
RNA preparations
Total RNA was prepared by the guanidinium thiocyanatephenol chloroform method. 15 The RNA was diluted to 0.1 g/l and stored at −80°C in 10 l aliquots. cDNA synthesis cDNA synthesis was made of 1 g of total RNA resuspended in 10 l DEPC H 2 O and 2.5 l 100 pmol/l random hexamer (N6) primer. It was incubated at 65°C for 5 min and placed on ice. 13.5 l McDNA-mix (1 l RNase inhibitor 40 units/l (Boehringer Mannheim, Germany), 5 l 5 × first strand buffer (250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl 2 ), 2 l 100 mM DTT, 2.5 l 10 mM (each) dNTP, 2.5 l MoMLV RT 200 units/l (Gibco-BRL) was added and the sample was incubated in 37°C for 45 min.
First PCR All PCRs were done in a 50 l reaction volume containing 1.5 U AmpliTaq Gold DNA polymerase (Perkin-Elmer, New Jersey, USA), 0.2 mM (each) dNTP, 25 pmol of a specific primer and 75 pmol of a random primer in the first PCR and 25 pmol of both primers in the second PCR. Two microliters cDNA was used as a template in the first PCR, 2 l of the isolated PCR products of the first PCR was used as template in the second PCR. In the first PCR, the polymerase was activated by heating to 95°C for 15 min and the reaction run 25 cycles in a GeneAmp 9600 (Perkin-Elmer), with denaturation at 95°C for 1.20 min, annealing at 62°C for 1.20 minutes, and extension at 72°C for 3 min and a last cycle of 72°C for 10 min. 10 l of the reaction mixture was electrophoresed in a 1.5% (wt/vol) agarose gel and stained with ethidium bromide.
Dynabead-streptavidin purification
The PCR products were separated by a dynabead-streptavidin purification. Dynabeads M280-streptavidin (Dynal, Oslo, Norway) were prewashed twice in 1 × B&W buffer (5.0 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 1.0 M NaCl) and eluted in 2 × B&W buffer. Forty microliters of dynabeads (6.7 × 10 8
Figure 2
Agarose gel and restriction analysis of PCR products. 
Table 1
Oligonucleotide primers used in the PCR and sequencing of MLL/AF10 chimerical products beads/ml) and 40 l of the PCR product were mixed and incuSecond PCR and purification of PCR products bated at room temperature in a shaker for 30 min. The beads were washed twice in 1 × B&W buffer using a magnet to sediTwo microliters of the purified PCR products was used for the second PCR where a MLL primer located downstream of the ment the beads in the tubes during supernatant removal. The bound fragments were denatured in 8 l 0.1 M NaOH for first primer, and a Tag primer specific for the conserved 5Ј end of random primers were used. In the second PCR, the 10 min and neutralized with 4 l 0.2 M HCl, 1 l 0.1 M TrisHCl, pH 8.0 and 17 l H 2 O.
polymerase was activated at 95°C for 15 min and the PCR run mRNA including exon 5 and the 3Ј AF10 mRNA from position 1931. Previously, 10 MLL-AF10 translocations have been described affecting both adult and pediatric leukemias. 12, 16 In the seven pediatric cases the translocations were mapped to a restricted region within the AF10 cDNA sequence (base positions 787 (single case), 883 (two cases) and 979 (four cases)). In the three adult cases the points of translocation were scattered over the AF10 gene (base positions 589, 2110, 2222 of the cDNA sequence). These observations could suggest that information 3Ј to the base position 979 in the cDNA sequence of AF10 may be crucial for the development of leukemia in young individuals. 12 The translocation we describe here does not, however, support the notion that the points of AF10 junction for the pediatric leukemias are restricted to a smaller region (between base positions 787 and 979), as we determined the point of junction in a pediatric leukemia to base position 1931. Our data also suggest that the AF10 junctions in pediatric leukemias may be scattered over the AF10
Figure 4
Gel analysis of control PCR of the fusion mRNA. The gene in the t(10;11) translocations. However, some 3Ј AF10 Several methods can be employed to characterize new chromosomal translocations in leukemic cells. Standard cytogenetic analysis is a powerful screening tool to detect gross 25 cycles at 95°C for 30 s, 62°C for 30 s, 72°C for 1.5 min and a last cycle of 72°C for 10 min. Ten microliters of the chromosomal abnormalities. In addition, since many genes involved in chromosomal translocations are already known, reaction mixture was electrophoresed in a 1.5% agarose gel and fragments of sizes bigger than 300 bp were purified from cytogenetic analysis of a new translocation may determine one partner of the translocation to be a gene already known a 3% agarose gels by centrifugation for 10 min at 9500 g through siliconized glass wool (Merck, Darmstadt, Germany) .
to be involved in previously described translocations. Though Southern blotting techniques using chromosomal DNA can be Samples were extracted with 1 vol 1/1 phenol/chloroform and ethanol precipitated.
alternatives to and supplement cytogenetical methods, these methods require as ART-PCR that one of the genes involved in the translocation is already known and they provide no information about the partner of recombination.
Restriction analyses and sequencing
Given these considerations, the ART-PCR method, described here, may be useful in identifying new partners to For patient samples with unknown translocations restriction analyses of fragments were done before sequencing. Restricknown genes involved in translocations. Furthermore, the cDNA sequence covering the junction can easily be detertion enzyme analyses were done in 20 l reactions containing 16 l purified PCR fragment, 2 l New England Biolab (MA, mined and subsequently molecularly cloned. Information of the sequence may then directly identify the partner gene if USA) (NEB) buffer 2, and 2 l BsmI (6 U/l; NEB) and incubated at 37°C for 1 h. The reaction products were electrophorsequence data is already available in the DNA sequence database. Alternatively, the sequence information can be used for esed in a 4% agarose gel. Fragments were sequenced using the protocol for Dye Terminator Cycle Sequencing Ready cloning and characterization of the partner gene (or cDNA sequence). Knowledge of the DNA sequence in the junction Reaction Kit (Perkin-Elmer), and done at 96°C for 10 s, 55°C for 5 s and 60°C for 4 min for 25 cycles, using either primer region is important in the designing of oligonucleotide primers used in single or multiplex PCR procedures for screening 16940 or Primer Tag. Homology searches were done using FASTA and BLAST programs in the GCG sequence analysis samples from patients with leukemia. package (Genetics Computer Group, Madison, WI, USA).
